-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $38

Benzinga·05/12/2026 10:57:06
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $48 to $38.